N/A N=40 Effect of Prewarming on Microcirculatory Response
Coronary Artery Bypass Graft Triple Vessel
Primary: Recovery Slope — 2.8; 3.1 % / sec (recovery slope unit)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction
Cardiovascular Disease
Primary: Main Effect of Treatment on the Ferric Reducing Antioxidant Potential (FRAP) Changes in Response to 4 Walnut Treatments — -26; 28; 9; -135 umol Trolox equivalents…
Phase 3 N=972 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Number of Participants With Adverse Events (AEs) — 950; 780; 516 Participants
N/A N=47 Online Peer Networked Collaborative Learning for Managing Depressive Symptoms
Depression
Primary: Patient Health Questionnaire - 9 (PHQ-9) - Depression Severity Module — -5.4; -4.8; -1.1 units on a scale — p=< .001
N/A N=20 Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults
Human Immunodeficiency Virus
Primary: Rectal Tissue Concentrations of Ralegravir and Dolutegravir — 5308; 810 ng/g — p=1.0
Phase 1 N=34 Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.
Meningitis, Meningococcal, Serogroup B
Primary: Safety: Severity Summary of Solicited and Unsolicited Adverse Events — 67; 92; 70; 3 AEs
N/A N=30,804 Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With RSV-associated Hospitalization — 1.5; 1.5; 0.8; 0.7 percentage of participants
Phase 3 N=617 Safety and Efficacy of Cariprazine in Patients With Schizophrenia
Schizophrenia
Primary: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. — -14.3; -20.2; -23.0; -21.2 Units on a Scale…
N/A N=105 IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)
Major Depressive Disorder · Anxiety Disorders
Primary: Patient Health Questionnaire - 9 (PHQ-9) - Depression Severity Module — 12.5; 8.4; 6.4 units on a scale — p=<.001
N/A N=86 Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Osteoporosis · Bone Fracture
Primary: Proportion of Change in Mean Trabecular Bone Score — .00238 Proportion of change
N/A N=50 Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device
Femoral Arteriotomy Closure
Primary: Number of Participants With Major Complications — 3 Participants
N/A N=714 Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
Prostatic Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events — 32; 2; 8; 1 Participants
N/A N=1,274 Incentives in Diabetic Eye Assessment by Screening
Diabetes · Diabetic Retinopathy
Primary: Number of Patients Attending Screening Appointment — 34; 17; 10 Participants
N/A N=16 Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears
Meniscus Tear
Primary: WOMET Score — 57.5; 99.4; 37.0; 63.9 units on a scale
Phase 2 N=115 Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 13.2 Months